



August 13, 2020

Listing Department Code: 532321

BSE Limited

 $\hbox{P J Towers, Dalal Street, Fort,}\\$

<u>Mumbai – 400001</u>

Listing Department Code: CADILAHC

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,

Bandra (E),

Mumbai – 400051

Re.: <u>Press Release</u>

Dear Sir / Madam,

Please find enclosed a Press Release dated August 13, 2020 titled "Zydus Cadila receives final approval from the USFDA for Sevelamer Carbonate Tablets".

The contents of the Press Release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and investors' at large.

Thanking you,

Yours faithfully,

For, CADILA HEALTHCARE LIMITED

DHAVAL N. SONI

COMPANY SECRETARY

Encl.: As above



Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

Release Press Release

Zydus Cadila receives final approval from the USFDA for Sevelamer Carbonate Tablets

Ahmedabad, August 13, 2020

Zydus Cadila has received final approval from the USFDA to market Sevelamer Carbonate Tablets (US RLD - Renvela Tablets) in the strength of 800 mg.

The drug is a phosphate binder and is used to control phosphorus levels in people with chronic kidney disease who are on dialysis. It helps prevent hypocalcemia (low levels of calcium in the body) caused by elevated phosphorus. The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 296 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

CIN: L24230GJ1995PLC025878